Peripheral arterial disease with intermittent claudication — indication assessment
Atherosclerotic obstruction of the lower-limb arteries producing exertional ischaemic symptoms, with objective confirmation by ankle–brachial index or imaging.
§1Assessment
§1.1Definition
Atherosclerotic obstruction of the lower-limb arteries producing exertional ischaemic symptoms, with objective confirmation by ankle–brachial index or imaging.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Maximum walking distance
- Pain-free walking distance
- Ankle–brachial index
- Major adverse limb events
§1.3State of the evidence
The Institute assesses 1 compound in this indication, drawing on 4 trial records and 0 evidence syntheses. [1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.